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Introduction
The introduction of drug-eluting stents (DES), through the dramatically decreased incidence of in-stent restenosis (ISR) it yielded, is considered a revolution in the field of percutaneous coronary intervention (PCI) 1 . The further-improved safety profile of newgeneration DES led to their unrestricted use in increasingly complex patients and lesions 2, 3 so that latest European guidelines 4 state that DES should be considered by default in all clinical conditions and lesion subsets. However, DES have not eliminated the ISR issue as a recent angiographic study shown that these new-generation devices are still plagued by a 12% rate of angiographic ISR 5 .
Paclitaxel-coated balloon (PCB) were initially studied in bare-metal stent (BMS) ISR against plain old balloon angioplasty (POBA) [6] [7] [8] [9] or paclitaxel-eluting stent (PES) 10 , since it appeared very attractive to locally deliver a drug without the introduction of additional stent layers. These studies showed an early and sustained benefit of PCB over POBA on angiographic and clinical outcomes whereas only a trend towards better clinical results was achieved against PES despite significantly improved angiographic findings with PCB. There are increasing data regarding treatment of DES-ISR by PCB angioplasty either compared to POBA 11, 12 , PES 13 or both techniques 14 . These studies demonstrated that late lumen loss (LLL), diameter stenosis (%) and major adverse cardiac events (MACE) were consistently and significantly lower in patients treated by PCB than in patients treated by POBA 11, 12 .
Moreover, PCB angioplasty matched the angiographic and clinical results of repeat stenting with PES 13, 14 . These data recently led the European Society of Cardiology to give a class IA recommendation for the use of PCB in BMS and DES-ISR 4 . In this setting, the main goal of this observational study was to confirm these positive findings in an unselected French patient population under routine use.
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Methods
Objectives
The aim of the GARO (Groupe des Angioplasticiens de la Région Ouest) registry was to evaluate the safety and efficacy of PCB angioplasty to treat DES-ISR in native coronary
arteries. This was a non-randomized, open-label, single arm, observational registry conducted in 13 French centers (see list in Appendix). The protocol was approved by the French national ethics committee as part of the parent 'All-Comers Registry' which also included other indications beside DES-ISR. All patients gave written informed consent. Data were captured using an established electronic case report form with built-in plausibility checks previously proved useful and efficient in related observational PCB studies 15, 16 . The two coordinating investigators (MB,JB) were responsible to contact co-investigators whenever the e-CRF plausibility checks indicated discrepancies.
Patients
All consecutive patients >18 years old with DES-ISR, treated by PCB angioplasty were enrolled in this registry. All Mehran types of ISR 17 in native coronary arteries with reference vessel diameters between ≤ 2.5 and ≤ 3.5 mm and ≤ 22 mm in length were eligible.
ISR had to reduce the reference vessel diameter either by ≥70% or ≥50% with documented ischemia corresponding to the target lesion. Major exclusion criteria were: cardiogenic shock, Killip class III heart failure, pregnant/lactating women, severe valvular heart disease, patients with a life-expectancy < 5 years and patients with contraindications to dual-antiplatelet therapy or known hypersensitivity to acetylsalicylic acid, clopidogrel, paclitaxel, or heparin.
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Endpoints and definitions
The primary endpoint was clinically driven target lesion revascularization at 9 months (TLR) as a composite of re-PCI and coronary artery bypass grafting (CABG). Secondary endpoints included the procedural success rate, definite acute/subacute vessel thrombosis rates as defined by the ARC criteria 18 . Moreover, major adverse cardiac events (MACE), defined as the composite of TLR, death of cardiac or unknown origin and myocardial infarction (MI),
were also documented. Myocardial infarction was diagnosed with corresponding ECG changes and/or cardiac enzyme elevations according to each institution's routine diagnostic algorithms.
Procedure
Patients received 500 mg of aspirin before the intervention or were receiving longterm treatment. A clopidogrel loading dose of 300-600 mg was administered. Heparin (50-100UI/kg) was administered upon insertion of the sheath. Intracoronary Nitrates (0.2 mg)
were administered 2 minutes before baseline and final reference angiography performed in two near-orthogonal views. The paclitaxel-coated (3μg/mm²) PTCA catheter based on the Paccocath® Technology (SeQuent® Please, B.Braun Melsungen AG) was used accordingly to previously published guidelines 19 . Especially, special attention was given to proper predilation of the target lesion and PCB was not used unless residual diameter stenosis was ≤ 30% after balloon predilation. A 60s PCB inflation at a minimum of 10 bar was recommended unless not tolerated by the patient (hypotension and/or severe ventricular arrhythmia due to ischemia). Additional stents were implanted in case of significant recoil, residual stenosis or dissections after PCB therapy. Lesion length and vessel reference diameter were assessed using online quantitative coronary angiography or visual estimation.
Dual-antiplatelet therapy was recommended for at least 9 months after the procedure.
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Quantitative Coronary Angiography
Angiographic data were routinely collected pre-and post-procedure with the use of identical projections and analyses. Quantitative analysis of the coronary angiographic images was done by 2 independent operators in an independent angiographic core laboratory. A difference of ±3% of the relative stenosis between the two operators was deemed acceptable.
If the discrepancy exceeded this value, a third operator decided upon the result of the assessment. In case of insufficient quality of the angiogram, the patient was rejected. The CAAS II research system (Quantcor QCA, Pie Medical Imaging, Maastricht, The Netherlands) was used for automated contour detection and quantification.
Statistical analysis
Continuous variables are expressed as mean±SD. Normality was tested using Kolmogorov-Smirnov test. Continuous variables were compared using unpaired t-test or Mann-Whitney U-test as appropriate. Categorical variables are presented as counts and percentages and were compared with the use of Fisher's exact or χ2 test, as appropriate. Timeto-event data are shown as Kaplan-Meier curves and were compared using the log-rank test.
Kaplan-Meier curves reports end points that were censored at the time of first event or at 9 months, whichever occurred first. All reported p-value are 2-sided and a p-value <0.05 was considered significant. Analyses were done with SAS version 9.2 (SAS Institute Cary, NC USA) and SPSS version 20.0 (IBM, Munich, Germany). Subgroup analyses were planned for DES-ISR subgroups consisting of PES-ISR and non-PES-ISR due to potential differences in clinical outcomes. Baseline angiographic characteristics (Table 2) The majority of patients had single-vessel disease (56.8%) with a target lesion located in the left anterior descending artery in the left anterior descending coronary artery in 37.6%, the left circumflex coronary artery in 27.6% and the right coronary artery in 29.0%. The most represented target stent types were PES (21.2%), sirolimus-eluting stent (SES, 38.4%) and new-generation everolimus-eluting stent (EES, 29.1%). Diffuse ISR pattern was present in 44.3% of patients.
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Results
Patients
Quantitative coronary angiographic analysis and procedural characteristics
The mean lesion length and reference vessel diameter were 12.59±8.87mm and 2.77±0.78mm respectively ( Table 3 ). The mean residual stenosis diameter was 15.6±12.5%
post-index procedure (Table 3) . Diameter stenosis was smaller in the PES-ISR group Table 4 . Procedural success of the PCB interventions was reported for 207 lesions (98.6%) with a borderline significant difference (p=0.046) between the PES-ISR and non-PES-ISR groups (Table 4) .
In-hospital and accumulated 9-months clinical events
There were no differences between the PES-ISR and the non PES-ISR groups during hospitalization (Table 5) . Overall there was only one cardiac death and one TLR up to the point of discharge. Complete follow-up (by telephone: 79.7% or by hospital visit: 20.3%) was achieved in 187 patients (90.8%) at a mean of 8.9±0.84 months. The primary endpoint of TLR occurred in 13 patients (7.0%) whereas 10.7% of patients suffered a MACE. 9-month rates of MI and cardiac death were 4.8% and 2.1% respectively ( Figure 1 , Table 5 ).
There was no difference between the PES-ISR and the non PES-ISR groups in the 9-month rates of TLR (3.6% vs. 7.0%, p=0.314), MACE (7.2% vs. 9.2%, p=0.738), MI (4.8% vs. 4.4%, p=0.772), cardiac death (4.8% vs. 1.4%, p=0.791) as assessed by Kaplan-Meier method ( Figure 2 ). Regarding TLR rates, these results were consistent across various subgroups. However, patients with a delay between DES implantation and DES-ISR < 12
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months presented a clear trend towards higher rate of MACE (Figure 3) . Although, treatment of new-generation EES-ISR resulted in higher absolute 9-months rates of TLR (9.7% vs.
4.7%) and MACE (15.3% vs. 6.8%), these differences did not reach statistical significance.
Discussion
The main finding of the present study is that PCB angioplasty to treat DES-ISR achieved acceptably low rates of TLR and MACE at 9 months in a French unselected patient population which is in agreement with previously conducted DES-ISR trials.
DES-ISR and BMS-ISR share some common mechanisms such as stent underexpansion, stent fracture, stent malapposition, and non-uniform strut distribution but DES-ISR also presents specific stimuli of neointimal thickening like localized hypersensitivity, non-uniform drug deposition, polymers and drug resistance 20, 21 . This may explain why treatment of DES-ISR remains highly challenging. Indeed, a recent multicenter retrospective analysis of 392 patients with 481 DES-ISR lesions, which were treated with repeat DES stenting in 66% of cases, showed rates of recurrent restenosis ranging from 29.0 to 65.6% depending on the initial pattern of DES-ISR 21 . Some authors 9, 22 suggested that DES-ISR identifies a high-risk group of patients in which the best available antirestenotic therapy to date has failed and PCB angioplasty in this setting, like repeat DES stenting, has shown worse results than in the treatment of BMS-ISR 9, 12 . The results of the present study showing higher absolute rates of TLR and MACE after treatment of new-generation EES-ISR support this idea of a very challenging group of patients exhibiting signs of resistance to our current "gold-standard".
Previous studies investigating the efficacy and safety of PCB angioplasty to treat DES-ISR reported rates of TLR ranging from 2.9% at 6 months 9 to 22.1% at 12 months 14 and rates of MACE ranging from 6.6% 9 to 23.5% 14 at the same time points (Table 6 ). Thus, the clinical outcomes of the present study are in agreement with previously published trials 9,11-14 . Postprocedural diameter stenosis ( whereas Habara and coworkers documented the highest remaining degree of stenosis (25.7%±7.2%). These discrepancies seems attributable to lower post-procedural MLD in studies by Habara et al. 9, 11 which highlights the adamant importance of a proper pre-dilation of the lesion before using a PCB with regard to angiographic outcomes. These procedural results does not necessarily relate to clinical outcomes (Table 6 ) however they greatly influence the conclusion of studies using an angiographic measure at follow-up as their primary end-point. Intermodality studies comparing PCB angioplasty to repeat DES stenting might especially be prone to this bias as repeat stenting usually results in higher postprocedural MLD 13, 14, 23 . Moreover, the number of stent layers may introduce additional bias.
Rittger et al 12 reported that 53.6% of the ISR lesions treated in their patient population had at least 2 metal layers the latest being a DES which may explain the relatively high late lumen loss in the PCB and POBA groups (0.43± 0.61 mm vs. 1.03± 0.77 mm, p<0.001). Our belief is that a proper pre-dilation is of adamant importance in the setting of DES-ISR. Cutting and especially the more flexible and deliverable scoring balloons may be particularly attractive as they allow device anchoring in the lesion, deep incision of neointimal tissue and prevent "watermelon seeding" effect which might be responsible for edge dissection and unplanned stent implantation. Whether these devices provide better results in the treatment of DES-ISR is currently the subject of ongoing clinical trials (21).
Our finding that PCB angioplasty results in similar clinical outcomes after treatment of PES-ISR and non PES-ISR is in line with the conclusion of the ISAR-DESIRE 2 study 24 . In The time course between DES implantation and ISR seems to be an important factor to consider when addressing the issue of DES-ISR. We showed a higher rate of MACE in patients with a delay between DES implantation and DES-ISR < 12 months. The shorter the
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time frame from DES implantation to DES-ISR is, the less likely ISR is to be caused by neointimal hyperplasia whereas mechanical factors probably play a crucial role. It has also been shown that early ISR presentation was correlated to diffuse ISR patterns which may explain the worse results we observed in the sub-group of patients with a short delay between DES implantation and ISR as the morphological pattern of DES-ISR is an important predictor of clinical outcomes, especially TLR 20 .
By definition a study limitation of all-comers registries is a less stringent control of data collection. Moreover, source data monitoring was only conducted whenever discrepancies were detected by the electronic data capture system. As a consequence, some under-reporting may have occurred in the present study. Owing to the evaluation of PCB angioplasty in routine clinical practice, we did not provide an angiographic follow-up and the database did not include information about intracoronary imaging techniques as their use to identify underlying mechanical factors was left to the discretion of the operator in this reallife setting. However, rates of 20% and even 42% of stent under-expansion were reported respectively in the setting of BMS-ISR (29) and DES-ISR (30). Thus, the crucial importance of identifying these mechanical issues cannot be enough emphasized to reach better results when dealing with DES-ISR.
Conclusion
PCB angioplasty to treat DES-ISR delivered an acceptably low 9-month TLR rate in a French unselected patient population which is in agreement with previously conducted DES-ISR trials. No difference was seen between PES-ISR and non-PES-ISR patients treated with PCBangioplasty. Cardiovascular and lesion related risk factors were not predictors of MACE.
However, if DES-ISR occurred within 12 months the risk of MACE at 9 months was higher in these early DES-ISR patients after PCB angioplasty. CI= confidence interval; DES= drug-eluting stents; ISR= in-stent restenosis; MACE= major adverse cardiac events; OR=odds-ratio PES= paclitaxel-eluting stent.
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Figure legends
Reference categories are: non PES-ISR; DES-ISR delay < 1 year; focal ISR, no diabetes mellitus, no hypertension, no hyperlipidemia. M A N U S C R I P T Values are mean ± SD or n (%).
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ISR= in-stent restenosis; PES= paclitaxel-eluting stent; STEMI= ST-elevation myocardial infarction. ii Percentage of lesions with data available about ISR classification (n=205). Values are mean ± SD or n (%).
A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT
PCI= percutaneous coronary intervention; PCB= paclitaxel-coated balloon. Other abbreviations as in table 1 and 2.
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